Prime Medicine (PRME) Share-based Compensation (2021 - 2026)

Prime Medicine (PRME) has 6 years of Share-based Compensation data on file, last reported at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 18.25% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $28.2 million (up 6.37% YoY), and the FY2025 full-year result was $29.3 million, up 12.28% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.6 million, up from $4.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $12.7 million in Q3 2025 and bottomed at $1.1 million in Q1 2022.
• The 5-year median for Share-based Compensation is $4.5 million (2025), against an average of $4.7 million.
• The widest annual swing landed in 2024, when Share-based Compensation surged 209.88%; it then declined 24.0% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $2.6 million in 2022, then jumped by 72.07% to $4.4 million in 2023, then soared by 34.14% to $5.9 million in 2024, then declined by 24.0% to $4.5 million in 2025, then increased by 2.86% to $4.6 million in 2026.
• The last three Share-based Compensation figures came in at $4.6 million (Q1 2026), $4.5 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.

Peer Comparison